SAMHSA Advisory: Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns

New SAMHSA Advisory: Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns SAMHSA has issued a new advisory on “Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns”. This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy. It is critical that the general public be made aware of the potential harms associated with CBD use, and parents, in particular, should be advised to not let their children use non-FDA-approved CBD products.

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download

Copyright © 2025 - NADDI. All Rights Reserved.

Disclaimer / Privacy Policy / Copyright Policy

Log in with your credentials

Forgot your details?